⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117020 | 0.83 | — | — | |
| SCHEMBL2557201 | 0.76 | — | — | |
| SCHEMBL3813203 | 0.68 | — | — | |
| SCHEMBL15416697 | 0.67 | — | — | |
| SCHEMBL3133035 | 0.65 | — | — | |
| SCHEMBL14745567 | 0.65 | — | — | |
| SCHEMBL9706522 | 0.63 | — | — | |
| SCHEMBL19302350 | 0.63 | — | — | |
| SCHEMBL2361898 | 0.63 | — | — | |
| SCHEMBL5598073 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221646-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118084940-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240109851-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| CN-112399874-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-112041311-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-4247783-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MACROCYCLIC MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-116457334-A | Processes and intermediates for preparing macrocyclic MCL1 inhibitors | 吉利德科学公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20230013713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-4065567-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20150166990-A1 | THERAPEUTIC OLIGONUCLEOTIDES COMPRISING PYRAZOLOTRIAZINE NUCLEOTIDE ANALOGUES | BIO-LAB LTD. (IL) | 2015-06-18 | — | — | US | disclosed |
| US-20150141490-A1 | PYRAZOLOTRIAZOLYL NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDES COMPRISING THEM | BIO-LAB LTD. (IL) | 2015-05-21 | — | — | US | disclosed |
| EP-2855679-A1 | THERAPEUTIC OLIGONUCLEOTIDES COMPRISING PYRAZOLOTRIAZINE NUCLEOTIDE ANALOGUES | QBI Enterprises Ltd. (IL) | 2015-04-08 | — | — | EP | disclosed |
| EP-2854813-A1 | PYRAZOLOTRIAZOLYL NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDES COMPRISING THEM | Bio-lab Ltd. (IL) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013179292-A1 | THERAPEUTIC OLIGONUCLEOTIDES COMPRISING PYRAZOLOTRIAZINE NUCLEOTIDE ANALOGUES | QBI ENTERPRISES LTD. (IL) | 2013-12-05 | — | — | WO | disclosed |
| WO-2013179289-A1 | PYRAZOLOTRIAZOLYL NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDES COMPRISING THEM | BIO-LAB LTD. (IL) | 2013-12-05 | — | — | WO | disclosed |
| US-5661186-A | MELATONERGIC EFFECT; CENTRAL NERVOUS SYSTEM DISODERS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0728738-A1 | Tetralinyl- and indanyl-ethylamides having melatonergic activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-28 | — | — | EP | disclosed |
| US-4939128-A | Antiischemic agents; circulatory disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-07-03 | — | — | US | disclosed |
| EP-0339486-A2 | Ester of ascorbic acid 2-phosphate | Takeda Chemical Industries, Ltd. (JP) | 1989-11-02 | — | — | EP | disclosed |